Recce’s (ASX:RCE) lead compound RECCE® 327 was found to be well tolerated with no adverse events in an independent study in large animals.
RECCE® 327 is a synthetic compound currently being developed to fights against viruses and bacteria, including superbugs, even after repeated use.
The study dosed two dogs with saline (control) and three with RECCE® 327 at 70 mg/kg, respectively, by intravenous infusion over 4 hours.
There were no adverse clinical signs and no apparent test article-related effects on body weight and blood pressure noted during the study.
In conclusion, the intravenous infusion of RECCE® 327 at 70 mg/Kg over four hours was well tolerated.
The company is encouraged by these results and will now focus on pre-clinical study of intravenous infusion of RECCE® 327 being developed as a potential treatment for antibiotic-resistant sepsis.
The issue of antibiotic resistance continues to make news. At least 2 million people in the U.S. alone are infected by bacteria that are resistant to common antibiotics and 23,000 die each year.
Recently, big pharmaceutical companies have initiated a major push to establish a global alliance to fight antibiotic-resistant superbugs.
Recce’s share price has increased by more than 50% since the start of 2017, last trading at $0.25.